These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11115503)

  • 1. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100.
    Borén J; Ekström U; Agren B; Nilsson-Ehle P; Innerarity TL
    J Biol Chem; 2001 Mar; 276(12):9214-8. PubMed ID: 11115503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
    Boren J; Lee I; Zhu W; Arnold K; Taylor S; Innerarity TL
    J Clin Invest; 1998 Mar; 101(5):1084-93. PubMed ID: 9486979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500-->Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins.
    Durovic S; März W; Frank S; Scharnagl H; Baumstark MW; Zechner R; Kostner GM
    J Biol Chem; 1994 Dec; 269(48):30320-5. PubMed ID: 7982944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.
    Flood C; Gustafsson M; Pitas RE; Arnaboldi L; Walzem RL; Borén J
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):564-70. PubMed ID: 14726411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial defective apolipoprotein B100: clinical characteristics of 54 cases.
    Rauh G; Keller C; Kormann B; Spengel F; Schuster H; Wolfram G; Zöllner N
    Atherosclerosis; 1992 Feb; 92(2-3):233-41. PubMed ID: 1632851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering.
    Chatterton JE; Schlapfer P; Bütler E; Gutierrez MM; Puppione DL; Pullinger CR; Kane JP; Curtiss LK; Schumaker VN
    Biochemistry; 1995 Jul; 34(29):9571-80. PubMed ID: 7626627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100.
    Schewe CK; Schuster H; Hailer S; Wolfram G; Keller C; Zöllner N
    Eur J Clin Invest; 1994 Jan; 24(1):36-41. PubMed ID: 8187806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function.
    Myant NB; Gallagher JJ; Knight BL; McCarthy SN; Frostegård J; Nilsson J; Hamsten A; Talmud P; Humphries SE
    Arterioscler Thromb; 1991; 11(3):691-703. PubMed ID: 1674216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
    Véniant MM; Zlot CH; Walzem RL; Pierotti V; Driscoll R; Dichek D; Herz J; Young SG
    J Clin Invest; 1998 Oct; 102(8):1559-68. PubMed ID: 9788969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric assessment of LDL ligand function for detection of heterozygous familial defective apolipoprotein B-100.
    Raungaard B; Heath F; Hansen PS; Brorholt-Petersen JU; Jensen HK; Faergeman O
    Clin Chem; 2000 Feb; 46(2):224-33. PubMed ID: 10657378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the proteoglycan binding site in apolipoprotein B48.
    Flood C; Gustafsson M; Richardson PE; Harvey SC; Segrest JP; Borén J
    J Biol Chem; 2002 Aug; 277(35):32228-33. PubMed ID: 12070165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.
    Borén J; Olin K; Lee I; Chait A; Wight TN; Innerarity TL
    J Clin Invest; 1998 Jun; 101(12):2658-64. PubMed ID: 9637699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The binding of very low density lipoprotein remnants to the low density lipoprotein receptor in familial defective apolipoprotein B-100.
    Maher VM; Gallagher JJ; Myant NB
    Atherosclerosis; 1993 Aug; 102(1):51-61. PubMed ID: 8257452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects.
    Arnold KS; Balestra ME; Krauss RM; Curtiss LK; Young SG; Innerarity TL
    J Lipid Res; 1994 Aug; 35(8):1469-76. PubMed ID: 7989871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) in subjects with familial defective apolipoprotein B100.
    Perombelon YF; Gallagher JJ; Myant NB; Soutar AK; Knight BL
    Atherosclerosis; 1992 Feb; 92(2-3):203-12. PubMed ID: 1385954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100.
    Corsini A; Mazzotti M; Villa A; Maggi FM; Bernini F; Romano L; Romano C; Fumagalli R; Catapano AL
    Atherosclerosis; 1992 Mar; 93(1-2):95-103. PubMed ID: 1596308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of an asparagine to lysine mutation at amino acid 3516 of apolipoprotein B on low-density lipoprotein receptor binding.
    Gaffney D; Pullinger CR; O'Reilly DS; Hoffs MS; Cameron I; Vass JK; Kulkarni MV; Kane JP; Schumaker VN; Watts GF; Packard CJ
    Clin Chim Acta; 2002 Jul; 321(1-2):113-21. PubMed ID: 12031600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100.
    Rauh G; Schuster H; Fischer J; Keller C; Wolfram G; Zöllner N
    Klin Wochenschr; 1991 May; 69(7):320-4. PubMed ID: 2067318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a).
    Cheesman EJ; Sharp RJ; Zlot CH; Liu CY; Taylor S; Marcovina SM; Young SG; McCormick SP
    J Biol Chem; 2000 Sep; 275(36):28195-200. PubMed ID: 10837476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans.
    Goldberg IJ; Wagner WD; Pang L; Paka L; Curtiss LK; DeLozier JA; Shelness GS; Young CS; Pillarisetti S
    J Biol Chem; 1998 Dec; 273(52):35355-61. PubMed ID: 9857078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.